---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000050"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:33:16.147768+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Keros receives positive FDA feedback on KER-050 MDS program; Phase 3 design aligned

## Summary
- FDA feedback resulted in general alignment on design and endpoints for proposed pivotal Phase 3 trial of KER-050 (elritercept) in MDS.
- Company to host corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. ET.
- Expects to complete enrollment of Phase 2 TROPOS trial evaluating KER-012 (cibotercept) in PAH in Q4 2024.

## SEC filing metadata
- accession: 0001664710-24-000050
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000050/0001664710-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000050/kros-20240604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000050
- JSON: https://secwatch.observer/filing/0001664710-24-000050.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.